| 626- SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor |
| 636- ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009) |
| 639- A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies |
| 640- Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial - ISRCTN99462035. |
| 641- Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide |
| 643- A Randomized, Double-blind, Phase 2a Clinical Trial to Study the Efficacy and Safety of Lamotrigine for Treatment of Patients with Dementia with Lewy Bodies |
| 682- REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease |
| 702- GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation |
| 703- WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update |
| 704- The HIIT-Home4Parkinson’s study |
| 717- Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience |
| 722- Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial |
| 728- Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial |
| 730- Comparing Ring and Directional Globus Pallidus Stimulation Effects on Parkinson’s Gait |
| 733- PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson's Disease through objective measurements and patient reported outcomes - a multicenter randomized controlled trial |
| 737- Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism |
| 738- The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD) |
| 742- LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics |
| 746- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease (PADOVA): Rationale, Design, and Baseline Data |
| 762- First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease |
| 928- Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial |
| 1133- Safety and effectiveness of staged bilateral MR-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson’s disease: study protocol |
